ACAD · Acadia Pharmaceuticals Inc
$19.58
-0.37 (-1.85%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$3.44B
Shares
172.31M
Volume · Oct 5
489.19K
Avg daily vol (3M)
1.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.95
Open$20.01
Day$19.88–20.24
52W close$19.89–30.57
Avg vol 30d2.0M
Short int9.7M · 5.6% float · 7.2d
Short vol56%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Dec 13, 2026
Est · unconfirmed
· in 10 wks
filed Aug 5, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.14B
Trailing 12 months
Net income (TTM)
$380.48M
Trailing 12 months
Revenue growth YoY
+16.4%
Year over year
Operating margin
7.6%
Trailing 12 months
P / E (TTM)
8.9
Trailing earnings · reciprocal yield 11.2%
FCF yield
4.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.5%
Year over year · more shares
Price change (1Y)
-6.7%
Trailing year
Short interest
5.6%
Latest settlement · 7.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−26%
below
RSI (14)
16
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−7%
trailing
YTD return
−25%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
1 of 355 funds reported for Sep 30 · net +38 sh shares
Insider flow
Distributing
Net -$432.7K over 90 days · 100% sells
Short interest
Falling
5.61% of float · ▼ -0.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
355 holders — near 3-yr high, broad support
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+40%
Y/Y
Gross margin
94%
contracting
EPS growth
+69%
Y/Y
Free cash flow
$105.1M
Valuation
P/E 8.9
below peers
Quant / Vol
risk profile
Volatility
39%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 4, 2026
Total 2026 revenue
· full year 2026
Initiated
$1.24B – $1.3B
prior FY $1.07B
midpoint +18.5% Y/Y
Gross to net
· full year 2026
Initiated
23% – 25%
R&d expenses
· full year 2026
Initiated
$355M – $380M
DAYBUE net sales
· full year 2026
Initiated
$480M – $510M
NUPLAZID net sales
· full year 2026
Initiated
$760M – $790M
Guided vs delivered
· last 3 settled
Total revenue
Full Year 2024
guided $930M – $980M
$957.8M
In line
Net sales
for the year
guided $480M – $515M
$484.15M
In line
Net sales
full year 2020
guided $430M – $450M
$441.76M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
16
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $27 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
1 of 355 funds reported for Sep 30 · net +38 sh shares
Insider flow
Distributing
Net -$432.7K over 90 days · 100% sells
Short interest
Falling
5.61% of float · ▼ -0.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
355 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20
Now $20 · 1%
Range high $31
vs 200-day avg -18%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACAD
this stock
Acadia Pharmaceuticals Inc
|
$3.44B | -25.3% | +40.4% | 8.9 | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACAD | -3.5% | -28.4% | -7.0% | -1.0% | -25.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.3% | -27.9% | -19.2% | -1.9% | -38.2% |
Key facts
CIK
1070494
CUSIP
004225108
13F (30d)
11 filings
8 filers
Visit website
Investor relations